Učitavanje...
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells
BACKGROUND: Docetaxel is one of the primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to docetaxel therapy and their disease will continue to progress. The mechanisms by which resistance develops are still inc...
Spremljeno u:
| Izdano u: | Prostate |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5448975/ https://ncbi.nlm.nih.gov/pubmed/28485104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23358 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|